PDL, Roche settle drug-royalties fight; Swiss immigration limits would hit Roche, Novartis; 8th Circuit backs verdict against Novartis in Zometa case;

@FiercePharma: Gilead in talks with Indian drugmakers to sell Sovaldi at cut-rate prices. Story | Follow @FiercePharma

@TracyStaton: From FiercePharmaMarketing: UCB nabs Asian marketing rights to hot Biogen MS drugs. More | Follow @TracyStaton

@EricPFierce: My colleague Mark Hollmer offers a thoughtful analysis of pacemakers after having one put in. Check it out. Item | Follow @EricPFierce

@CarlyHFierce: More Humira sales gains help AbbVie meet forecasts. News | Follow @CarlyHFierce

> PDL Biopharma said it had settled its royalty disputes with Roche ($RHHBY), in a deal that grants it royalties on sales of the cancer drugs Avastin, Herceptin, Kadcyla, and Perjeta, as well as the asthma drug Xolair and eye drug Lucentis. Report

> A Swiss proposal to restrict immigration would interfere with drugmakers' ability to recruit skilled workers, Roche ($RHHBY) CEO Severin Schwan said, noting that half of the company's R&D staff are not Swiss, and nor is he. Report

> A U.S. appeals court affirmed a failure-to-warn verdict against Novartis ($NVS), even though the doctor who prescribed its drugs Zometa and Aredia said he didn't read the drug warnings. Report

> The Swedish drugmaker Recipharm tapped two local banks to advise on a potential stock market listing this year. Report

> Vertex Pharmaceuticals ($VRTX) cut the ribbon on its new Boston headquarters, which will house all of its area workers, including 1,200 already in place and another 100 moving in this quarter. Report

> Endo Health Solutions ($ENDP) wrapped up its sale of its HealthTronics unit to Altaris Capital for up to $130 million in cash and milestones. Report

Medical Device News

@FierceMedDev: FDA: Kids with diabetes can use DexCom's continuous glucose monitor. Story | Follow @FierceMedDev

@MarkHFierce: Here's my perspective, as a patient, on the pacemaker industry. Editor's corner | Follow @MarkHFierce

@MichaelGFierce: Lupin stakes a claim on the sterile injectables market. News | Follow @MichaelGFierce

@EmilyWFierce: Endo waves goodbye to HealthTronics for $130M. Report | Follow @EmilyWFierce

> Boston Scientific appears to turn a corner as sales growth gains momentum. More

> Thermo Fisher closes $13.6B Life Tech acquisition. Item

Biotech News

@FierceBiotech: Eisai readies applications for thyroid cancer drug after SFJ delivers PhIII success. More | Follow @FierceBiotech

@JohnCFierce: Furiex preps for buyout talks after IBS drug looks promising in PhIII. News | Follow @JohnCFierce

@DamianFierce: Big Pharma superteam joins NIH to share data, discover new drugs. Story | Follow @DamianFierce

@EmilyMFierce: Mechanism that boosts bone growth could aid osteoporosis drug design. Article via FierceBiotech Research | Follow @EmilyMFierce

> NEA backs $14M round for a biotech startup focused on autism disorder. More

> Acucela spots a $162M Japanese IPO to get its eye drug into focus. Read

Biotech Research News

> $40M gift from stem cell agency will fund new genomics initiative. Item

> Exposure to acid turns adult cells into stem cells. More

> Merck halts drug testing on chimpanzees. News

> Mechanism that boosts bone growth could aid osteoporosis drug design. Report

> Stem cell signaling protein spurs cancer spread. Story

> Epilepsy drug reverses fatty liver disease in obese mice. Article

Pharma Manufacturing News

> Daiichi Sankyo is bringing the hammer down on Ranbaxy. More

> Amgen is halting Epogen manufacturing in Colorado. Story

> Abbott is closing a plant in Puerto Rico as Mexico's Neolpharma expands. Article

> Alexion buys vial-filling facility in Ireland. News

> Lupin stakes a claim on the sterile injectables market. Report

> Sources: Recipharm looks at doing an IPO to expand cash. Item

And Finally... A sugary diet can double the risk of heart disease, a new study found. Report

Suggested Articles

Pfizer will exit its Perth, Australia sterile injectables manufacturing site by 2024 as part of a global production reorganization effort.

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.